Browse by Poster Presenter

Skip to main content

CTOS 2024 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

I
Ibáñez del Prado, Celia

Complutense University
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Celia Ibáñez del Prado
Favorite
Ibanez, Glorymar

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Glorymar Ibanez
Favorite
Ibarra, Joe

Ann & Robert H Lurie Children's Hospital of Chicago
(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Joe Ibarra
Favorite
Ibrahim, Toni

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Toni Ibrahim
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Toni Ibrahim
Favorite
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Toni Ibrahim
Favorite
Id Said, Badr

MD Anderson Cancer Centre
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Badr Id Said
Favorite
Ignar, Diane

Chordoma Foundation
(P 02) A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS
Diane Ignar
Favorite
Ikegami, Masachika

Division of Cellular Signaling, National Cancer Center Research Institute
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Masachika Ikegami
Favorite
Ikeuchi, Kyoko

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
Kyoko Ikeuchi
Favorite
Ikuta, Kunihiro

Nagoya university
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Kunihiro Ikuta
Favorite
Imagama, Shiro

Nagoya university hospital
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Shiro Imagama
Favorite
Imura, Yoshinori

Osaka University Graduate School of Medicine/Orthopaedic Surgery
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
Yoshinori Imura
Favorite
(P 324) BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA
Yoshinori Imura
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Yoshinori Imura
Favorite
Ingley, Katrina

University College London Hospital
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Katrina Ingley
Favorite
Ingram, Davis

MD Anderson Cancer Center
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Davis Ingram
Favorite
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Davis Ingram
Favorite
Inoue, Akitomo

Osaka University Graduate School of Medicine/Orthopaedic Surgery
(P 324) BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA
Akitomo Inoue
Favorite
Inoue, Satoru

Daiichi Sankyo Co., LTD.
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Satoru Inoue
Favorite
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Satoru Inoue
Favorite
Iranpur, Khurshid

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Khurshid Iranpur
Favorite
Irudayaraj, Joseph

University of Illinois Urbana-Champaign
(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Joseph Irudayaraj
Favorite
Irvin, Boston

University of Miami Miller School of Medicine
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Boston Irvin
Favorite
Isakoff, Michael

Connecticut Children's Medical Center
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Michael Isakoff
Favorite
Ishibashi, Yuki

The University of Tokyo, Department of Orthopaedic Surgery
(P 57) CLINICAL GENOMIC PROFILING OF MALIGNANT GIANT CELL TUMOR OF BONE: A RETROSPECTIVE ANALYSIS USING A REAL-WORLD DATABASE
Yuki Ishibashi
Favorite
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Yuki Ishibashi
Favorite
Ishihara, Shin

University of British Columbia
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Shin Ishihara
Favorite
Ishizuka, Jeffrey

Yale New Haven Health
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Jeffrey Ishizuka
Favorite
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Jeffrey Ishizuka
Favorite
Isler, Marc

CIUSSS Est-de-l'Île-de-Montréal
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Marc Isler
Favorite
Italiano, Antione

Bergonié Institute
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Antione Italiano
Favorite
Itkin, Boris

SQCCCRC
(P 68) FEASIBILITY OF FIVE-DRUG INTERVAL-COMPRESSED CHEMOTHERAPY FOR ADOLESCENTS AND YOUNG ADULTS WITH EWING SARCOMA FAMILY TUMORS IN THE REAL-WORLD SETTING IN OMAN
Boris Itkin
Favorite
(P 193) DISTRIBUTION OF CONNECTIVE TISSUE TUMORS BY HISTOLOGY AND DEGREE OF MALIGNANCY IN A SINGLE INSTITUTION IN OMAN
Boris Itkin
Favorite
Iwata, Shintaro

National Cancer Center Hospital Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Shintaro Iwata
Favorite
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Shintaro Iwata
Favorite
(P 249) TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT
Shintaro Iwata
Favorite
Ixtlamati-Nava, Diana

Texas Tech University Health Sciences Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Diana Ixtlamati-Nava
Favorite
Iyer, Rema

National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Rema Iyer
Favorite